Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality

University of Michigan

Status and phase

Completed

Phase 2

Conditions

Chronic Pancreatitis

Insulin Resistance

Normal or Mildly Abnormal Stool Fat Levels

Treatments

Drug: Placebo

Drug: Pioglitazone

Study type

Interventional

Funder types

Other

Industry

NIH

Identifiers

NCT00782795

R21AA017271 (U.S. NIH Grant/Contract)

CP-PENQEX-1R21AA017271

1R21AA017271-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to determine if study drug (Pioglitazone) treatment will improve pre-diabetes (insulin resistance) or ealy diabetes and improve clinical symptoms (pain) or laboratory evidence of chronic pancreatitis.

The goal of the investigators is to gather information from this study to help gain understanding of a potential therapy for chronic pancreatitis.

Full description

The pancreas is a digestive organ that secretes insulin (and other hormones) into the blood for regulating blood sugar (glucose) and digestive enzymes into the intestine for digesting and absorbing nutrients consumed in meals. Chronic pancreatitis is a progressive clinical disease of the pancreas, associated with swelling (inflammation), scarring (fibrosis) and loss of normal functioning tissue. Patients develop diabetes mellitus (elevated blood sugar), malabsorption of nutrients, weight loss and pain. Presently chronic pancreatitis is considered an irreversible condition because the mechanisms responsible for chronic pancreatitis are poorly understood and no therapy is proven. However, recent studies provide important clues that oral medications (Thiazolidinediones) used to treat diabetes mellitus might improve or reverse features of chronic pancreatitis, including elevated sugar or diabetes, reduced secretion of digestive enzymes, and pancreatic swelling and scarring.

Note: Takeda Pharmaceuticals North America (TPNA) provided pioglitazone and placebo pills with identically appearance until June 28, 2010, approximately the middle of the study.

Enrollment

64 patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Insulin resistance or mild diabetes mellitus
Symptoms of abdominal pain
Xray test showing damage to the pancreas
Normal or mildly abnormal stool fat levels

Exclusion criteria

Mentally disabled patients
Women who are planning pregnancy, pregnant or lactating/nursing
Chronic pancreatitis is due to other specific conditions
- Autosomal dominant pancreatitis
- Classic cystic fibrosis with lung involvement
- Autoimmune pancreatitis
- Pancreatic cancer
- Biliary obstruction (non-pancreatic cause)
- Abdominal trauma
- Hypercalcemia
- Hypertriglyceridemia
Surgical resection of the head of the pancreas
Alcohol consumption within prior 2 months
Specific medical conditions
- Gastric surgery
- Celiac sprue
- Crohns disease
- Heart failure
- Kidney failure
- Cirrhosis or liver disease
- Osteoporosis
- Blood clotting disorder
- Visual problems
- Low albumin
- Low BMI
Specific medications *Diabetes drug treatment is allowed except for short-acting insulin, long-acting insule more than 15 units daily, pioglitazone, rosiglitazone, orlistat, acarbose, miglitol or voglibose.